Engineered immune cells take on tough childhood cancers in new trial

NCT ID NCT04539366

First seen Nov 03, 2025 · Last updated May 01, 2026 · Updated 28 times

Summary

This early-stage trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying the GD2 protein. The main goals are to see if the cells can be made successfully, find the safest dose, and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California, 94304, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.